Figure 2 Pathology of scleroderma renal crisis

Slides:

Advertisements

Similar presentations

Antioxidant Treatment Prevents Renal Damage and Dysfunction and Reduces Arterial Pressure in Salt-Sensitive Hypertension by Niu Tian, Kristina D. Thrasher,

Advertisements

Figure 2 Electromechanical properties of OIHPs

Figure 6 Selected examples of TERS applications in material systems

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 4 Interplay between acute kidney injury (AKI),

Figure 6 Effects of adiponectin on podocyte function

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 4 Expression of coagulation protease receptors in renal cells

Figure 4 Interactions between adipose, the microbiome and kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanisms of kidney injury in the setting of obesity

Figure 2 Physiological changes in the renal system in pregnancy

Figure 2 Proinflammatory mechanisms in CKD

Figure 1 Circadian changes in energy metabolism and immune responses in CKD Figure 1 | Circadian changes in energy metabolism and immune responses in CKD.

Figure 1 Pathological features of lupus nephritis subtypes

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Role of the kidney in glucose homeostasis

Figure 4 Effect of dapagliflozin on HbA1c and body weight

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Pathologic features of obesity-related glomerulopathy (ORG)

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 The bioavailability of phosphate differs according to the protein source Figure 6 | The bioavailability of phosphate differs according to the.

Figure 7 The efficacy of phosphate-binder therapy

Figure 2 Expression of complement activation products in renal samples

Figure 2 The network of chronic diseases and their mutual influences

Figure 1 The burden of chronic kidney disease (CKD)

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Societal costs for the care of patients with chronic kidney disease in the UK Figure 3 | Societal costs for the care of patients with chronic.

Figure 2 Glomerular pathology in mice and humans with diabetic nephropathy Figure 2 | Glomerular pathology in mice and humans with diabetic nephropathy.

Figure 2 Podocyte dysfunction is a common feature of renal injury

Figure 1 Currently recognized factors that influence the development of scleroderma renal crisis Figure 1 | Currently recognized factors that influence.

Figure 1 Sequential impact of diabetes platforms, genetic backgrounds and accelerators on albuminuria and kidney pathology in mouse models of diabetic.

Figure 1 Acute kidney injury and chronic kidney disease

Figure 2 The continuum of acute kidney injury (AKI),

Figure 4 Model of changes in the serum levels

filtration rate (GFR), and sodium (Na+) excretion

Figure 4 Effects of glucagon-like peptide 1 (GLP-1) and

Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Cell-surface markers for NP cell differentiation

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Clinical correlates of neurodegeneration in MS

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 The nephron-centric model of renal transplant fibrosis based on the injury-related molecular events observed in biopsy samples in the first year.

Figure 3 Biologics that attenuate effector responses in the kidney

Figure 3 Serum phosphate level is associated with

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Regulation of TGF-β1/Smad signalling by microRNAs (miRs) in tissue fibrosis Figure 3 | Regulation of TGF-β1/Smad signalling by microRNAs (miRs)

Figure 1 The relationship between health fitness and pathogen load

This Month in AJKD American Journal of Kidney Diseases

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Pathophysiological events and preventive

Figure 2 Biologics that target CD4+ T helper (TH)-cell subsets

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Patient, facility, health-care system and industry factors

Figure 4 The relationship between the time-dependent changes in the expression of immunoglobulin, mast cell, acute kidney injury (AKI), and fibrillar collagen.

Figure 4 Intracellular distribution and

Figure 4 4D printing schemes and time-evolving structure geometries

Figure 2 Haemodynamic alterations in obesity

Proportion of patients in each World Health Organization functional class (WHO-FC) at the time of pulmonary arterial hypertension-associated systemic sclerosis.

Figure 4 Treponema pallidum invasion

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Diffusio-osmotic process for osmotic energy conversion

Nat. Rev. Mater. doi: /natrevmats

Effect of placebo (n=88) and bosentan (n=80) on the co-primary end-point pulmonary vascular resistance (PVR) in the EARLY (Endothelial Antagonist Trial.

Presentation transcript:

Figure 2 Pathology of scleroderma renal crisis Figure 2 | Pathology of scleroderma renal crisis. The hallmark of scleroderma renal crisis is a proliferative, obliterative arteriolar vasculopathy with (a) hypertensive vascular damage, thrombotic vascular occlusion, glomerular ischaemic collapse, and diffuse tubular degeneration (b), onion skinning, and (c)intimal myoid accumulation and adventitial fibrosis. Parts a and c reproduced with permission from Hindawi Publishing Corporation © Batal, I. et al. Int. J. of Rheumatol. 2010, 543704 (2010). Part b reproduced with permission from Hindawi Publishing Corporation © Shanmugam, V. K. and Steen, V. D. Int. J. of Rheumatol., 2010, 538589 (2010). Parts a and c reproduced with permission from Hindawi Publishing Corporation © Batal, I. et al. Int. J. of Rheumatol. 2010, 543704 (2010). Part b reproduced with permission from Hindawi Publishing Corporation © Shanmugam, V. K. and Steen, V. D. Int. J. of Rheumatol., 2010, 538589 (2010). Woodworth, T. G. et al. (2016) Scleroderma renal crisis and renal involvement in systemic sclerosis Nat. Rev. Nephrol. doi:10.1038/nrneph.2016.124